Event Type
Disclosure
Voluntary
Variant
8-K
and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as
Other Events Planned proof-of-concept clinical trial in DME On January 20, 2026, the Company announced indication expansion for oral NLRP3 inhibitor BGE-102. •
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by BioAge Labs, Inc. dated January 20, 2026. 104 Cover Page In